Login to Your Account

Deal Carries $890M Potential

Novartis, Antisoma Enter Deal: $100M Near-Term For AS1404

By Randall Osborne

Friday, April 20, 2007
Roche's loss became Novartis' gain - maybe - in the increasingly competitive cancer space occupied by vascular disrupting agents (VDAs), where Antisoma plc holds a strong position. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription